Indivior shares drop on 2025 revenue decline forecast

(Alliance News) - Indivior PLC on Thursday warned of a significant drop in revenue and profit for ...

Alliance News 20 February, 2025 | 1:24PM
Email Form Facebook Twitter LinkedIn RSS

(Alliance News) - Indivior PLC on Thursday warned of a significant drop in revenue and profit for 2025, as increased competition from generic drugmakers is expected to weigh on sales of its opioid addiction treatment, Suboxone.

Shares in Indivior were down 17% at 719.45 pence on Thursday afternoon in London.

The Richmond, Virginia-based maker of medicines to treat substance use disorders forecast net revenue between USD955 million and USD1.03 billion for 2025, down 17% at the midpoint. Adjusted operating profit is expected to fall sharply to between USD185 million and USD225 million.

Chief Executive Officer Mark Crossley said the decline is primarily due to "an expected decrease in Suboxone film net revenue of greater than 50% from intensified generic pricing activity along with the potential for a fifth generic entrant."

Indivior swung to a pretax loss of USD43 million for 2024, compared to a profit of USD1 million the previous year, despite an 8.7% rise in net revenue to USD1.19 billion from USD1.09 billion. Diluted earnings per share fell to a loss of USD0.36, down from earnings of USD0.01 in 2023.

For the three months ended December 31, net revenue edged up slightly to USD298 million from USD293 million. However, pretax profit declined to USD31 million from USD61 million, with diluted EPS for the quarter falling to USD0.07 from earnings of USD0.38 a year earlier.

The company said it ended 2024 with a better-than-expected final quarter, driven by 20% year-on-year revenue growth in its long-acting injectable Sublocade. However, previously disclosed transitory factors and increasing competition in the US opioid treatment market weighed on overall results.

Indivior said it has streamlined its cost base and identified savings exceeding USD100 million, with approximately half to be reinvested in Sublocade and its pipeline for opioid use disorder treatments, while the remainder will be used to support profitability.

By Eva Castanedo, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2025 Alliance News Ltd. All Rights reserved.

Email Form Facebook Twitter LinkedIn RSS

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
Rating
Indivior PLC Ordinary Share 696.89 GBX -4.80 -

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

© Copyright 2025 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures